伊立替康和贝伐单抗治疗胶质母细胞瘤a综述

S. Khair-ul-Bariyah, M. Shahid
{"title":"伊立替康和贝伐单抗治疗胶质母细胞瘤a综述","authors":"S. Khair-ul-Bariyah, M. Shahid","doi":"10.15228/2014.V04.I01.P01","DOIUrl":null,"url":null,"abstract":"Glioblastoma is a common brain tumor having comparatively poor prognosis. Bevacizumab and irinotecan are found to be effective in the treatment of recurrent glioblastoma. The present review covers investigations made on the mentioned drugs in the past decade. As compared to other chemotherapeutic agents, the drugs have shown greater activity and overall survival when used as monotherapeutic agents or in combination with other drugs. Still some work needs to be done in establishing clear role of both the drugs in newly diagnosed glioblastoma, especially, role of irinotecan needs clarity.","PeriodicalId":19815,"journal":{"name":"Pakistan Journal of Chemistry","volume":"145 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2014-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Irinotecan and Bevacizumab in Glioblastoma-A Review\",\"authors\":\"S. Khair-ul-Bariyah, M. Shahid\",\"doi\":\"10.15228/2014.V04.I01.P01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glioblastoma is a common brain tumor having comparatively poor prognosis. Bevacizumab and irinotecan are found to be effective in the treatment of recurrent glioblastoma. The present review covers investigations made on the mentioned drugs in the past decade. As compared to other chemotherapeutic agents, the drugs have shown greater activity and overall survival when used as monotherapeutic agents or in combination with other drugs. Still some work needs to be done in establishing clear role of both the drugs in newly diagnosed glioblastoma, especially, role of irinotecan needs clarity.\",\"PeriodicalId\":19815,\"journal\":{\"name\":\"Pakistan Journal of Chemistry\",\"volume\":\"145 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan Journal of Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15228/2014.V04.I01.P01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15228/2014.V04.I01.P01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

胶质母细胞瘤是一种常见的脑肿瘤,预后较差。贝伐单抗和伊立替康在治疗复发性胶质母细胞瘤方面被发现是有效的。本综述涵盖了过去十年对上述药物的研究。与其他化疗药物相比,这些药物在作为单一治疗药物或与其他药物联合使用时显示出更高的活性和总生存率。两种药物在新诊断的胶质母细胞瘤中的作用有待进一步明确,尤其是伊立替康的作用有待进一步明确。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Irinotecan and Bevacizumab in Glioblastoma-A Review
Glioblastoma is a common brain tumor having comparatively poor prognosis. Bevacizumab and irinotecan are found to be effective in the treatment of recurrent glioblastoma. The present review covers investigations made on the mentioned drugs in the past decade. As compared to other chemotherapeutic agents, the drugs have shown greater activity and overall survival when used as monotherapeutic agents or in combination with other drugs. Still some work needs to be done in establishing clear role of both the drugs in newly diagnosed glioblastoma, especially, role of irinotecan needs clarity.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信